CD105标记的肿瘤微血管密度与喉和下咽鳞状细胞癌侵袭转移的相关性研究  

The intratumor microvessel density marked by CD105 in laryngeal and hypopharyngeal squamous cell carcinomas and its correlation with tumor invasion and metastasis

作　　者：鲁建光[1] 肖玉丽[1] 阚轩[1] 金德均[1] 

机构地区：[1]哈尔滨医科大学第二临床医学院耳鼻咽喉-头颈外科,黑龙江哈尔滨150081

出　　处：《哈尔滨医科大学学报》2008年第4期341-343,347,共4页Journal of Harbin Medical University

基　　金：黑龙江省自然科学基金资助项目(D200631);哈尔滨医科大学第二临床医学院青年基金项目(200617)

摘　　要：目的探讨CD105标记的瘤内微血管密度(intratumor microvessel density,IMVD)与喉和下咽鳞状细胞癌侵袭转移的相关性。方法设计制作喉和下咽鳞状细胞癌组织芯片,应用免疫组化技术在组织芯片上检测CD105的表达,根据CD105的表达计算IMVD值,分析CD105标记的肿瘤微血管密度与喉癌和下咽癌临床和病理分期的相关性。结果原发癌和转移癌中CD105标记的IMVD值显著高于正常黏膜(P<0.001),原发癌和转移癌IMVD值无显著差异(P>0.05)。有淋巴结转移组IMVD值明显高于无淋巴结转移组(P<0.05),声门上型喉癌的IMVD值明显高于原发于其它部位的喉肿瘤(P<0.01),而IMVD值与肿瘤的分化程度、浸润范围以及病人的年龄、性别等因素无明显相关(P>0.05)。结论CD105标记的微血管密度与喉癌和下咽癌的侵袭转移密切相关,新生血管的形成是恶性肿瘤发生侵袭和转移的关键步骤,喉和下咽原发癌组织中新生血管数量的增多可能预示着肿瘤有发生颈淋巴结转移的趋势,可以作为估计其预后的参考指标之一。Objective To investigate the intratumor microvessel density （IMVD） marked by CD105 in laryngeal and hypopharyngeal squamous cell carcinomas （LHSCC） and the relation between the IMVD with tumor invasion and metastasis. Methods The tissue microarray of LHSCC was prepared and used to investigate the expression of CD105 by immunohistochemistry. The IMVD and the relationship between the IMVD and tumor biological behaviour were analyzed. Results The IMVDs marked by CD105 in primary cancer tissues and metastatic carcinomas were significantly higher than normal tissues （ P 〈 0. 001 ）, but there was no disparation between primary cancer tissues and metastatic carcinomas （P 〉 0.05 ）. In patients with lymph node metastasis, the IMVD was significantly higher than that of the group without lymph node metastasis（P 〈 0.05 ）. The IMVD of supraglottic carcinomas was significantly higher than that of other locations（P 〈0.01 ）. Conclusion The IMVD marked by CD105 significantly correlates with invasion and metastasis of LHSCC,it might become a referred index of prognosis appraisal of the LHSCC.

关 键 词：喉肿瘤 癌 鳞状细胞 下咽肿瘤 抗原 CD105 组织芯片 肿瘤血管发生 

分 类 号：R739.63[医药卫生—肿瘤] R329-33[医药卫生—临床医学]